A Comparative Study to Evaluate the Effectiveness between Synergic Activities of 0.1% Polyhexanide and Rigenase® (Fitostimoline® Plus spray) versus a Hydrating Formulation for the Topical Management of Rubbing Injuries Secondary to Atopic Dermatitis.
Eugenia Veronica Di Brizzi, Anna Balato, Stefano Caccavale, Amalia Lupoli, Carlo Panetti, Giuseppe Argenziano
{"title":"A Comparative Study to Evaluate the Effectiveness between Synergic Activities of 0.1% Polyhexanide and Rigenase® (Fitostimoline® Plus spray) versus a Hydrating Formulation for the Topical Management of Rubbing Injuries Secondary to Atopic Dermatitis.","authors":"Eugenia Veronica Di Brizzi, Anna Balato, Stefano Caccavale, Amalia Lupoli, Carlo Panetti, Giuseppe Argenziano","doi":"10.5826/dpc.1501a4906","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Managing rubbing injuries in atopic dermatitis is challenging and has a significant impact on patients' quality of life. Polyhexamethylene biguanide (PHMB) and Rigenase® (a patented Triticum vulgare extract) show promise in tissue repair and antimicrobial activity.</p><p><strong>Objective: </strong>The aim of this study was to compare the effectiveness of two topical treatments, Fitostimoline® Plus spray and a hydrating formulation with hyaluronic acid, in rubbing injuries secondary to atopic dermatitis.</p><p><strong>Materials and methods: </strong>This comparative study enrolled 68 patients with atopic dermatitis and rubbing injuries, randomly assigned to Group A (N=38) receiving Fitostimoline® Plus spray (0.1% PHMB and Rigenase®) or Group B (N=30) receiving a hyaluronic acid spray. The primary endpoint was the clinical lesion response at 10 days post-treatment. Secondary endpoints included pain reduction (Visual Analogue Scale, VAS) and patient satisfaction (Dermatology Life Quality Index, DLQI).</p><p><strong>Results: </strong>Group A had a significantly higher complete response rate (81.3% vs. 64.3%, P <0.001). Partial response rates were also higher in Group A (P = 0.045). Pain reduction was greater in Group A (VAS: 6.8 ± 1.2 to 2.4 ± 0.8) compared to Group B (7.1 ± 1.3 to 3.9 ± 1.0) (P <0.001). DLQI scores improved more in Group A (12.5 ± 3.5 to 3.2 ± 1.1) than in Group B (13.0 ± 3.2 to 6.5 ± 1.4) (P <0.001). Dermoscopic examinations showed significant skin barrier improvement in Group A (P <0.001).</p><p><strong>Conclusion: </strong>Fitostimoline® Plus spray, with 0.1% PHMB and Rigenase®, offers superior treatment for chronic lesions in atopic dermatitis, enhancing wound healing and patient quality of life.</p>","PeriodicalId":11168,"journal":{"name":"Dermatology practical & conceptual","volume":"15 1","pages":""},"PeriodicalIF":2.5000,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11928089/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatology practical & conceptual","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5826/dpc.1501a4906","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Managing rubbing injuries in atopic dermatitis is challenging and has a significant impact on patients' quality of life. Polyhexamethylene biguanide (PHMB) and Rigenase® (a patented Triticum vulgare extract) show promise in tissue repair and antimicrobial activity.
Objective: The aim of this study was to compare the effectiveness of two topical treatments, Fitostimoline® Plus spray and a hydrating formulation with hyaluronic acid, in rubbing injuries secondary to atopic dermatitis.
Materials and methods: This comparative study enrolled 68 patients with atopic dermatitis and rubbing injuries, randomly assigned to Group A (N=38) receiving Fitostimoline® Plus spray (0.1% PHMB and Rigenase®) or Group B (N=30) receiving a hyaluronic acid spray. The primary endpoint was the clinical lesion response at 10 days post-treatment. Secondary endpoints included pain reduction (Visual Analogue Scale, VAS) and patient satisfaction (Dermatology Life Quality Index, DLQI).
Results: Group A had a significantly higher complete response rate (81.3% vs. 64.3%, P <0.001). Partial response rates were also higher in Group A (P = 0.045). Pain reduction was greater in Group A (VAS: 6.8 ± 1.2 to 2.4 ± 0.8) compared to Group B (7.1 ± 1.3 to 3.9 ± 1.0) (P <0.001). DLQI scores improved more in Group A (12.5 ± 3.5 to 3.2 ± 1.1) than in Group B (13.0 ± 3.2 to 6.5 ± 1.4) (P <0.001). Dermoscopic examinations showed significant skin barrier improvement in Group A (P <0.001).
Conclusion: Fitostimoline® Plus spray, with 0.1% PHMB and Rigenase®, offers superior treatment for chronic lesions in atopic dermatitis, enhancing wound healing and patient quality of life.